Boyle KL, Leech E. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care (San Antonio) 2012;22:398–408.
Fujino K, Sperelakis N, Solaro RJ. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1988;63:911–922.
Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 2019;22:1127–1140.
Lombard CW, Jöns O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249–261.
Häggström J, Lord PF,Höglund K, et al. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. J Vet Intern Med 2013;27:1452–1462.
Boswood A, Gordon SG, Häggström J, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with preclinical myxomatous mitral valve disease receiving pimobendan or placebo: the EPIC study. J Vet Intern Med 2018;32:72–85.
Suzuki S, Fukushima R, Ishikawa T, et al. The effect of pimobendan on left atrial pressure in dogs with mitral valve regurgitation. J Vet Intern Med 2011;25:1328–1333.
Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008;22:1124–1135.
Boswood A, Häggström J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study–a randomized clinical trial. J Vet Intern Med 2016;30:1765–1779.
Roşca M, Lancellotti P, Popescu BA, et al. Left atrial function: pathophysiology, echocardiographic assessment, and clinical applications. Heart 2011;97:1982–1989.
Nakamura K, Osuga T, Morishita K, et al. Prognostic value of left atrial function in dogs with chronic mitral valvular heart disease. J Vet Intern Med 2014;28:1746–1752.
Höllmer M, Willesen JL, Tolver A, et al. Left atrial volume and function in dogs with naturally occurring myxomatous mitral valve disease. J Vet Cardiol 2017;19:24–34.
Osuga T, Nakamura K, Lim SY, et al. Repeatability and reproducibility of measurements obtained via two-dimensional speckle tracking echocardiography of the left atrium and time-left atrial area curve analysis in healthy dogs. Am J Vet Res 2013;74:864–869.
Caivano D, Rishniw M, Patata V, et al. Left atrial deformation and phasic function determined by 2-dimensional speckle tracking echocardiography in healthy dogs. J Vet Cardiol 2016;18:146–155.
Baron Toaldo M, Romito G, Guglielmini C, et al. Assessment of left atrial deformation and function by 2-dimensional speckle tracking echocardiography in healthy dogs and dogs with myxomatous mitral valve disease. J Vet Intern Med 2017;31:641–649.
Dermlim A, Nakamura K, Morita T, et al. The repeatability and left atrial strain analysis obtained via speckle tracking echocardiography in healthy dogs. J Vet Cardiol 2019;23:69–80.
Nakamura K, Kawamoto S, Osuga T, et al. Left atrial strain at different stages of myxomatous mitral valve disease in dogs. J Vet Intern Med 2017;31:316–325.
Caivano D, Rishniw M, Birettoni F, et al. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease. J Vet Cardiol 2018;20:102–114.
Cornell CC, Kittleson MD, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311–321.
Hori Y, Kunihiro S, Hoshi F, et al. Comparison of the myocardial performance index derived by use of pulsed Doppler echocardiography and tissue Doppler imaging in dogs with volume overload. Am J Vet Res 2007;68:1177–1182.
Hori Y, Taira H, Nakajima Y, et al. Inotropic effects of a single intravenous recommended dose of pimobendan in healthy dogs. J Vet Med Sci 2019;81:22–25.
Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996;119:609–615.
Ohte N, Cheng CP, Suzuki M, et al. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1997;282:23–31.
Bokník P, Neumann J, Kaspareit G, et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 1997;280:277–283.
Osuga T, Nakamura K, Morita T, et al. Effects of various cardiovascular drugs on indices obtained with two-dimensional speckle tracking echocardiography of the left atrium and time-left atrial area curve analysis in healthy dogs. Am J Vet Res 2015;76:702–709.
Ahtarovski KA, Iversen KK, Lønborg JT, et al. Left atrial and ventricular function during dobutamine and glycopyrrolate stress in healthy young and elderly as evaluated by cardiac magnetic resonance. Am J Physiol Heart Circ Physiol 2012;303:H1469–H1473.
Barbier P, Solomon SB, Schiller NB, et al. Left atrial relaxation and left ventricular systolic function determine left atrial reservoir function. Circulation 1999;100:427–436.
Fujimoto S. Effects of pimobendan, its active metabolite UD-CG 212, and milrinone on isolated blood vessels. Eur J Pharmacol 1994;265:159–166.
van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989;14:S1–S6.
Dernellis JM, Stefanadis CI, Zacharoulis AA, et al. Left atrial mechanical adaptation to long-standing hemodynamic loads based on pressure-volume relations. Am J Cardiol 1998;81:1138–1143.
Roşca M, Popescu BA, Beladan CC, et al. Left atrial dysfunction as a correlate of heart failure symptoms in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2010;23:1090–1098.
Imanishi J, Tanaka H, Sawa T, et al. Association of left atrial booster-pump function with heart failure symptoms in patients with severe aortic stenosis and preserved left ventricular ejection fraction. Echocardiography 2015;32:758–767.
Duygu H, Nalbantgil S, Ozerkan F, et al. Effects of levosimendan on left atrial functions in patients with ischemic heart failure. Clin Cardiol 2008;31:607–613.
Sarcinella F, Neves J, Maddox TW, et al. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease. Open Vet J 2020;9:375–383.
Lee J, Mizuno M, Mizuno T, et al. Pathologic manifestations on surgical biopsy and their correlation with clinical indices in dogs with degenerative mitral valve disease. J Vet Intern Med 2015;29:1313–1321.
Pagel PS, Kehl F, Gare M, et al. Mechanical function of the left atrium: new insights based on analysis of pressure-volume relations and Doppler echocardiography. Anesthesiology 2003;98:975–994.
McCallum JB, Stekiel TA, Bosnjak ZJ, et al. Does isoflurane alter mesenteric venous capacitance in the intact rabbit? Anesth Analg 1993;76:1095–1105.
Wouters PF, Van de Velde MA, Marcus MA, et al. Hemodynamic changes during induction of anesthesia with eltanolone and propofol in dogs. Anesth Analg 1995;81:125–131.
Coote JH. Myths and realities of the cardiac vagus. J Physiol 2013;591:4073–4085.
Advertisement
To determine the effects of IV administration of pimobendan on hemodynamic indices and indices of left atrial (LA) longitudinal strain by speckle-tracking echocardiography in healthy dogs.
6 healthy Beagles.
After the dogs were anesthetized, the right heart was catheterized and 2-D conventional and speckle-tracking echocardiography were performed before and after IV administration of 0.15 mg of pimobendan/kg. Speckle-tracking echocardiography was performed to assess the 3 LA phasic functions through LA deformation (longitudinal strain and strain rate) and volumetric analyses.
Pimobendan significantly increased stroke volume and cardiac output and decreased systemic vascular resistance. Pimobendan significantly improved left ventricular function assessed by the Tei index and LA booster pump function assessed by LA longitudinal strain and change in fractional volume during atrial systole. Indices of LA reservoir and conduit function were unchanged.
In healthy dogs, IV administration of pimobendan improved the indices of LA booster pump function but had no effect on the indices of LA reservoir and conduit functions. Further studies are needed to validate whether these results can be extrapolated to dogs with myxomatous mitral valve disease.